About 200 reports

  • 68.72% OF THE MARKET SHARE COMES FROM ORAL ADMINISTRATION

Tyvaso contains the active substance, treprostinil, for administration through oral inhalation.

  • Cardiovascular Disease
  • Actelion Ltd
  • Daiichi Sankyo Company
  • Novartis AG
  • United Therapeutics Corporation

Source: Azoth Analytics Estimates CAGR 2013-2017 ##. ##% CAGR 2018-2023 ##. ##% ##. ## ##. ## ##. ## ##. ## ##. ## ##. ## ##. ## ##. ## ##. ## ##. ## ##. ## Within the small molecule drug market, the vast majority of products re formulated for oral administration..

  • Cardiovascular Disease
  • World
  • Market Size
  • Baxter International Inc.
  • Gilead Sciences, Inc.

Moreover, patches are the best substitute for oral administration of medication when the route is unsuitable and also it improve the compliance over other dosage forms which require frequent dose administration.

  • Cardiovascular Disease
  • North America
  • World
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • SAFETY OF PEMAFIBRATE

TOWARDS THIS, SEVERAL OF THE PIPELINE ORAL TABLETS IN DEVELOPMENT SUCH AS BEMPEDOIC ACID AND GEMCABENE ONLY REQUIRE ONCE DAILY ORAL ADMINISTRATION.

  • Cardiovascular Disease
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company

Candesartan itself is poorly absorbed after oral administration; the ester prodrug, candesartan cilexetil, improves bioavailability.

  • Cardiovascular Disease
  • China
  • Demand
  • Trade
  • AstraZeneca China Inc.

CANDESARTAN ITSELF IS POORLY ABSORBED AFTER ORAL ADMINISTRATION; THE ESTER PRODRUG, CANDESARTAN CILEXETIL, IMPROVES BIOAVAILABILITY.

  • Cardiovascular Disease
  • China
  • Demand
  • AstraZeneca China Inc.
  • Sanofi-Synthelabo Inc.

The oral administration of bardoxolone methyl should increase its patient compliance compared to that of SC or IV therapies.

  • Cardiovascular Disease
  • United States
  • Forecast
  • Actelion Ltd
  • United Therapeutics Corporation

Unless this one [bococizumab] has better efficacy or more convenient administration, we won' t find the product attractive.

  • Cardiovascular Disease
  • World
  • Market Size
  • Amgen Inc.
  • AstraZeneca PLC

For example, a patient with a score of one might be prescribed an oral anticoagulant, warfarin, or one of the NOACs. "

  • Cardiovascular Disease
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company
  • Pfizer Inc.

THE PARTICIPANTS WERE DIVIDED INTO THREE GROUPS; GROUP A HAD ## PATIENTS WHO WERE ON ORAL MEDICATION, GROUP B HAD ## PATIENTS WHO WERE TAKING ORAL MEDICATIONS AND INSULIN INJECTIONS AND GROUP C HAD ## PATIENTS WHO WERE TAKING ORAL MEDICATIONS AND INSULIN INJECTIONS FOR IMPA

  • Cardiovascular Disease
  • Cell Therapy
  • Medical Biotechnology
  • Market Size
  • CardioCell LLC
  • 8.2.4 KEY CO-DEVELOPMENT DEALS 8.2.4.1 CO-DEVELOPMENT AGREEMENT BETWEEN NOVARTIS AND MOCHIDA PHARMACEUTICAL

It is formulated as film-coated tablets for oral administration.

  • Cardiovascular Disease
  • Market Size
  • Daiichi Sankyo Company
  • Merck & Co., Inc.
  • Novartis AG

Revatio' s reconstituted oral suspension contains ## mg/ mL for administration.

  • Cardiovascular Disease
  • United States
  • Actelion Ltd
  • Bayer AG
  • United Therapeutics Corporation

Heparin' s large size and high negative charge make oral administration difficult.

  • Cardiovascular Disease
  • World
  • Market Size
  • Pfizer Inc.
  • Sanofi S.A.
  • LOOP DIURETICS ARE THE MAINSTAY OF FIRST-LINE THERAPY FOR ADHF PATIENTS

In Japan (##. ##%) and the UK (##. ##%) it was furosemide oral.

  • Cardiovascular Disease
  • Japan
  • United States
  • Novartis AG
  • Orion Corporation
  • CKD-519 - DRUG PROFILE

It is administered through the oral route.

  • Cardiology
  • Cardiovascular Disease
  • Hospital
  • Therapy
  • Pfizer Inc.
  • SMALL MOLECULE TO INHIBIT CYP11B2 FOR HEART FAILURE - DRUG PROFILE

The drug candidate is administered orally.

  • Cardiovascular Disease
  • Therapy
  • United States
  • World
  • Product Initiative
  • Overview of the pivotal trial data for Uptravi in pulmonary arterial hypertension

FDA (2002) Food and Drug Administration approval letter: Remodulin.

  • Cardiovascular Disease
  • European Union
  • North America
  • United States
  • Actelion Ltd
  • CKD-519 - DRUG PROFILE

It is administered through the oral route.

  • Cardiology
  • Cardiovascular Disease
  • Hospital
  • Therapy
  • Pfizer Inc.
  • JNJ-26993135 - Drug Profile

Approximately forty patients will be randomized in a ##:## ratio to receive ubenimex or matching placebo, administered orally for a total of ## weeks.

  • Cardiovascular Disease
  • Therapy
  • World
  • Product Initiative
  • Celtaxsys, Inc.

It is an orally administered analgesic agent that exhibits a potent agonist activity on opioid receptor like -## (ORL-##) and mu opioid receptor.

  • Cardiovascular Disease
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • RIVAROXABAN - DRUG PROFILE

IT IS FORMULATED AS CAPSULES FOR ORAL ROUTE OF ADMINISTRATION.

  • Blood Disease
  • Cardiovascular Disease
  • United States
  • World
  • Product Initiative
  • DYB-186 - DRUG PROFILE

All subjects will receive a single oral administration of ##mg of apabetalone.

  • Cardiovascular Disease
  • United States
  • World
  • Company
  • Product Initiative
  • Clinical Trial profile. 859 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## ## United Kingdom Source: Glob

  • Acute Coronary Syndrome
  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • AstraZeneca PLC

They comprise one or more active ingredients and are generally mixed with suitable liquids for oral administration.

  • Cardiovascular Disease
  • Topical Delivery
  • North America
  • United States
  • Pfizer Inc.
  • SMALL MOLECULE TO ACTIVATE SOLUBLE GUANYLATE CYCLASE FOR HYPERTENSION AND PARENCHYMAL HEMORRHAGE - DRUG PROFILE

It is formulated as tablets for oral route of administration.

  • Cardiovascular Disease
  • Therapy
  • United States
  • World
  • NicOx S.A.

It is administered orally.

  • Cardiovascular Disease
  • Type 2 Diabetes
  • United States
  • Product Initiative
  • ViroMed Co., Ltd.

It is formulated as film coated tablets for oral route of administration.

  • Cardiovascular Disease
  • Therapy
  • World
  • Product Initiative
  • Novartis AG

Consistently, oral administration of O## to obese rats O## reduced plasma levels of both PCSK## and total cholesterol, as well as of triglycerides, providing evidence that O## acts as an orally active PCSK## inhibitor with dual beneficial effects on LDL receptor levels.

  • Cardiovascular Disease
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • Regeneron Pharmaceuticals, Inc.
  • JNJ-26993135 - DRUG PROFILE

Approximately forty patients will be randomized in a ##:## ratio to receive ubenimex or matching placebo, administered orally for a total of ## weeks.

  • Cardiovascular Disease
  • Pharmaceutical
  • United States
  • Product Initiative
  • Celtaxsys, Inc.
  • RIVAROXABAN - DRUG PROFILE

Prothrombin factor ##+## was initially elevated after Kcentra administration and returned to predose baseline levels by ## hours post dose, while TXA had no effect.

  • Cardiovascular Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative